The LANDMARK randomised controlled trial (RCT) for MYVAL THV, a pioneering medical device, has been published by The LancetThis trial proves India’s capability to set new standards in cardiovascular care, and revolutionises heart valve treatment worldwide. Meril Life Sciences, an India-based global medical device
